Budget impact of resmetirom for the treatment of adults with non-cirrhotic non-alcoholic steatohepatitis (NASH) with moderate to advanced liver fibrosis (consistent with stages F2 to F3 fibrosis)
The adoption of resmetirom on the formulary for the treatment of non-cirrhotic NASH with moderate-to-advanced liver fibrosis resulted in a moderate increase in budget impact with declining costs related to NASH progression.
Authors
- Jesse Fishman (ORCID: https://orcid.org/0009-0002-8729-7435)
- Zachary D. Smith (ORCID: https://orcid.org/0000-0002-9283-1957)
- Hélène Parisé (ORCID: https://orcid.org/0009-0006-4976-904X)
- Yestle Kim
- Eric Bercaw (ORCID: https://orcid.org/0009-0000-6471-9936)
Institutions
- Employee Benefit Research Institute (US)
- Madrigal Pharmaceuticals (United States) (US)
Publication Details
- Journal
- Journal of Medical Economics
- Published
- 2024-08-19
- DOI
- https://doi.org/10.1080/13696998.2024.2393952
- Citations
- 12
- Primary Topic
- Liver Disease Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 4.64
Funders
- Madrigal Pharmaceuticals